JP2019208419A - Method for predicting red acne - Google Patents
Method for predicting red acne Download PDFInfo
- Publication number
- JP2019208419A JP2019208419A JP2018106604A JP2018106604A JP2019208419A JP 2019208419 A JP2019208419 A JP 2019208419A JP 2018106604 A JP2018106604 A JP 2018106604A JP 2018106604 A JP2018106604 A JP 2018106604A JP 2019208419 A JP2019208419 A JP 2019208419A
- Authority
- JP
- Japan
- Prior art keywords
- acne
- rna
- red
- occurrence
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明は、赤ニキビの発生を予測する方法に関する。 The present invention relates to a method for predicting the occurrence of red acne.
ニキビは脂腺性毛包に生じる炎症性の皮膚疾患であって、医学的には尋常性ざ瘡を指し、ざ瘡、アクネとも呼ばれる。ニキビの発生に関係する主要な因子としては、角化因子（毛包の閉塞）、内分泌因子（ホルモンの刺激による皮脂分泌）、細菌性因子（アクネ菌Ｃｕｔｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）が挙げられる。すなわち、異常角化により毛包漏斗部が閉塞すると、毛包に皮脂が貯留し、面皰（白ニキビ）が形成される。この中で、アクネ菌が増殖すると炎症が起き、赤色丘疹（赤ニキビ）となる。赤ニキビは、皮膚面から***する針頭大から米粒大ぐらいの限局性の炎症性発疹である。赤ニキビは、痛みを伴うこともあり、進行すると膿疱を形成し、皮膚組織を犯してのう腫となる。その後の組織修復過程で、瘢痕が形成されたり、色素沈着が残ることもある。 Acne is an inflammatory skin disease that occurs in sebaceous hair follicles and medically refers to acne vulgaris, also called acne and acne. Major factors related to acne development include keratinizing factor (hair follicle obstruction), endocrine factor (sebum secretion by hormone stimulation), and bacterial factor (Acne fungus Cutibacterium acnes). That is, when the hair follicle funnel portion is closed due to abnormal keratinization, sebum accumulates in the hair follicle and comedones (white acne) are formed. In this, if acne bacteria proliferate, inflammation will be caused and it will become a red papule (red acne). Red acne is a localized inflammatory rash ranging from needle-head size to rice grain size that bulges from the skin surface. Red acne can be painful and, as it progresses, forms pustules and becomes a tumor that commits skin tissue. Subsequent tissue repair may cause scarring or pigmentation.
ニキビを予防又は改善するためには、ニキビの状態を把握するとともに、進行を予測し、進行に則した適切な処置をすることが理想的である。そのため、ニキビの進行を予測するための様々な検討がなされている。特許文献１には、皮膚試料中のＦＡＢＰ−５を測定し、正常な皮膚試料のＦＡＢＰ−５の測定値と対比し、発現の上昇をニキビの悪性化の指標とするニキビ肌の検査方法が記載されている。特許文献２には、ニキビ患者の血中の骨型ＡＬＰ（ＢＡＰ）濃度を測定することによりニキビの状態を評価する方法、さらに好中球の割合を測定して、その割合が高い場合にはニキビの素因をストレスであると特定し、ニキビ改善のためのアドバイスを行うことが提案されている。特許文献３には、血液中のＦｒｅＴ４、８−ＯＨｄＧ生成速度、鉄濃度、フェリチン量、ヘモグロビン量、ヘマトクリット量、コリンエステラーゼ活性、遊離脂肪酸量から選択される１〜２種類以上の測定値を指標として、ニキビのリスクを評価する方法が記載されている。しかし、これらは、ニキビ肌やニキビの状態、又はリスクの評価方法であり、ニキビの発生自体を的確に予測することは困難であった。また、アクネ菌の状態を指標としたニキビ発生の予測法はこれまでなかった。 In order to prevent or improve acne, it is ideal to grasp the state of acne, predict progression, and take appropriate measures according to the progression. Therefore, various studies have been made to predict the progress of acne. Patent Document 1 discloses a method for inspecting acne skin by measuring FABP-5 in a skin sample, comparing it with the measured value of FABP-5 in a normal skin sample, and using an increase in expression as an index of malignant acne. Has been described. Patent Document 2 discloses a method for evaluating the state of acne by measuring the concentration of bone type ALP (BAP) in the blood of acne patients, and the proportion of neutrophils is measured. It has been proposed to identify the predisposition to acne as stress and provide advice for acne improvement. Patent Document 3 uses as an index one or more measured values selected from FreT4, 8-OHdG production rate in blood, iron concentration, ferritin amount, hemoglobin amount, hematocrit amount, cholinesterase activity, and free fatty acid amount. A method for assessing acne risk is described. However, these are methods for evaluating acne skin, acne condition, or risk, and it has been difficult to accurately predict the occurrence of acne. Moreover, there has been no method for predicting acne occurrence using the state of acne as an index.
ニキビの過程において、最も重要な症状の一つが炎症、すなわち赤ニキビの発生である。ニキビの発生メカニズムの面からは、赤ニキビは白ニキビの次となっているが、実際には白ニキビを経ず、急に赤ニキビが発生することも多い。反対に、白ニキビができても、赤ニキビにならないことも多くある。赤ニキビの発生を予測するためには、赤ニキビの発生原因の変化を捉える必要がある。 In the process of acne, one of the most important symptoms is inflammation, the development of red acne. In terms of acne generation mechanism, red acne is next to white acne, but in practice, red acne often occurs suddenly without white acne. On the other hand, there are many cases where white acne does not become red acne. In order to predict the occurrence of red acne, it is necessary to capture changes in the cause of red acne.
赤ニキビにおいて最も重要な因子はアクネ菌である。赤ニキビは、面皰の中でアクネ菌が増殖することによって発生する。しかし、ニキビの人と健常人で、皮膚表面に常在するアクネ菌の数に違いはなく（非特許文献１）、またニキビ発生の前に皮膚表面のアクネ菌数が増加するという報告もない。つまり、皮膚表面に常在するアクネ菌の数を指標として、ニキビの発生を予測することは困難であった。 The most important factor in red acne is acne. Red acne is caused by the growth of acne bacteria in the comedones. However, there is no difference in the number of acne bacteria residing on the skin surface between acne and healthy people (Non-Patent Document 1), and there is no report that the number of acne bacteria on the skin surface increases before acne occurs. . In other words, it was difficult to predict the occurrence of acne using the number of acne bacteria resident on the skin surface as an index.
赤ニキビの発生を予測する方法の開発が望まれていた。 Development of a method for predicting the occurrence of red acne has been desired.
本発明者は、上記課題の解決に向け鋭意検討を行った結果、皮膚上に存在するアクネ菌のＲＮＡ量の変動を経時的に測定することにより、赤ニキビの発生を予測する方法を見出し、本発明を完成するに至った。 As a result of diligent studies for solving the above problems, the present inventors have found a method for predicting the occurrence of red acne by measuring the change in the RNA amount of acne bacteria present on the skin over time, The present invention has been completed.
すなわち、経時的に皮膚表面から採取したものを試料とし、試料中のアクネ菌のＲＮＡ量を指標とし、そのＲＮＡ量の増加から赤ニキビ発生を予測する方法である。 That is, this is a method of predicting the occurrence of red acne from an increase in the amount of RNA, using as an index the amount of acne bacteria in the sample collected from the skin surface over time.
本発明における赤ニキビとは、主として毛包漏斗部が閉塞した毛包の中でアクネ菌が増殖した炎症状態のことをいう。目視では、色は赤く、皮膚面から針頭大から米粒大ぐらいの大きさで***している。 The red acne in the present invention refers to an inflammatory state in which acne bacteria have proliferated in a hair follicle in which the hair follicle funnel is mainly blocked. Visually, the color is red, and it is raised from the skin surface to the size of the needle head size to the size of rice grains.
皮膚表面からの試料の採取方法としては、綿棒による拭き取り法（スワブ法）、洗い出し法（スクラブ法）、テープストリップ法、及び皮膚組織切除法（バイオプシー法）が挙げられるが、非侵襲的である点で、拭き取り法、洗い出し法、又はテープストリップ法が望ましい。拭き取り法や洗い出し法における採取液としては、ポリソルベート８０、ポリソルベート２０又はトリトンＸ−１００といった界面活性剤を添加した蒸留水、生理食塩液、リン酸緩衝液などを用いることができる。テープストリッピング法には、セロファンテープをはじめ、各種の市販されている粘着テープを用いることができる。 Methods for collecting samples from the skin surface include wiping with a cotton swab (swab method), washing out method (scrub method), tape strip method, and skin tissue excision method (biopsy method), but they are non-invasive In this respect, a wiping method, a washing method, or a tape strip method is desirable. As the collected liquid in the wiping method or washing-out method, distilled water, physiological saline, phosphate buffer, or the like to which a surfactant such as polysorbate 80, polysorbate 20 or Triton X-100 is added can be used. For the tape stripping method, various commercially available adhesive tapes including cellophane tape can be used.
試料を採取する皮膚としては、ニキビが発生する顔面（額、頬、顎、鼻など）、頭皮、胸部、又は背部を対象部位とできる。 As the skin from which the sample is collected, the target site can be a face (forehead, cheek, chin, nose, etc.), scalp, chest, or back where acne occurs.
試料の採取は経時的に行う。試料の採取時間の間隔は、１〜２４時間が好ましく、１２〜２４時間がより好ましい。試料採取の間隔が１時間より短いと操作が煩雑且つ不経済であり、２４時間より長いと赤ニキビの的確な予測が困難である。測定は２回以上続けて行う必要があり、３回以上続けて行うことがより好ましく、５回以上続けて行うことが最も好ましい。 Samples are collected over time. The interval between sample collection times is preferably 1 to 24 hours, and more preferably 12 to 24 hours. If the sampling interval is shorter than 1 hour, the operation is complicated and uneconomical, and if it is longer than 24 hours, it is difficult to accurately predict red acne. The measurement needs to be performed twice or more, more preferably three or more times, and most preferably five or more times.
測定するアクネ菌のＲＮＡとしては、ｒｉｂｏｓｏｍａｌ ＲＮＡ（ｒＲＮＡ）や特定のタンパクのｍｅｓｓｅｎｇｅｒ ＲＮＡ（ｍＲＮＡ）でも良く、これらの総量でも良い。ｒＲＮＡはリボソームを構成しており、生体内で最も多く存在するＲＮＡである。ｍＲＮＡは蛋白質に翻訳され得る塩基配列情報と構造を持ったＲＮＡである。ｒＲＮＡとしては、５ｓ、１６ｓ及び２３ｓの各ｒＲＮＡを対象とできる。特定のｍＲＮＡの例としては、ヒアルロニダーゼ、プロテアーゼ、リパーゼ、デヒドロゲナーゼ、エステラーゼ、セラミダーゼ、及びリゾチームが挙げられるが、これらに限定されない。 The RNA of acne bacteria to be measured may be ribosomal RNA (rRNA), messenger RNA (mRNA) of a specific protein, or the total amount thereof. rRNA constitutes a ribosome and is the most abundant RNA in the living body. mRNA is RNA having base sequence information and structure that can be translated into protein. As the rRNA, 5s, 16s and 23s rRNAs can be targeted. Examples of specific mRNAs include but are not limited to hyaluronidase, protease, lipase, dehydrogenase, esterase, ceramidase, and lysozyme.
ｒＲＮＡ量やｍＲＮＡ量の測定は、Ｃｏｍｐｌｅｍｅｎｔｒｙ ＤＮＡ（ｃＤＮＡ）への逆転写反応後、Ｐｏｌｙｍｅｒａｓｅ Ｃｈａｉｎ Ｒｅａｃｔｉｏｎ（ＰＣＲ）やリアルタイムＰＣＲによって行うことができる。ＲＮＡ総量の測定は、分光光度計によって行うことができる。 The measurement of the amount of rRNA and the amount of mRNA can be carried out by Polymerase Chain Reaction (PCR) or real-time PCR after a reverse transcription reaction to Complementary DNA (cDNA). The total RNA can be measured with a spectrophotometer.
ＰＣＲを用いる場合、ＰＣＲ産物をアガロースゲル電気泳動によって分離、エチジウムブロマイド染色を行い、ある試料の発色量を基準とした発色量の比較によって、対象とするｒＲＮＡやｍＲＮＡの相対的な量を求めることができる。 When PCR is used, PCR products are separated by agarose gel electrophoresis, ethidium bromide staining is performed, and the relative amount of target rRNA or mRNA is determined by comparing the amount of color developed based on the amount of color developed of a sample. Can do.
リアルタイムＰＣＲを用いる場合、Ｔｈｒｅｓｈｏｌｄ Ｃｙｃｌｅ（Ｃｔ値）によって、対象とするｒＲＮＡやｍＲＮＡの相対的な量を求めることができる。 When using real-time PCR, the relative amount of the target rRNA or mRNA can be determined by the Threshold Cycle (Ct value).
分光光度計を用いる場合、波長２６０ｎｍで測定を行い、ＲＮＡ総量を算出することができる。 When a spectrophotometer is used, the total RNA amount can be calculated by measuring at a wavelength of 260 nm.
対象としたＲＮＡの量が、一定の倍数以上に増加した時点、より詳しくはｎ時間前の量と比較して２（ｎ／２４）倍以上に増加した時点で、２４時間以内に起きる赤ニキビの発生が予測できる。 Red acne that occurs within 24 hours when the amount of the target RNA increases more than a certain multiple, more specifically, when it increases more than 2 (n / 24) times compared to the amount n hours ago. Can be predicted.
本発明の方法によれば、赤ニキビ発生の予測が可能である。さらに、検査対象の試料採取が非侵襲的、且つ容易であり、対象者の負担が少なく簡便に測定することができる。以上に加えて、赤ニキビの発生を予防する物質のスクリーニングを行うことができる。 According to the method of the present invention, occurrence of red acne can be predicted. Furthermore, sampling of a test object is non-invasive and easy, and the measurement can be easily performed with less burden on the subject. In addition to the above, screening for substances that prevent the occurrence of red acne can be performed.
次に本発明を詳細に説明するため、実施例を挙げるが、本発明はこれに限定されるものではない。 Next, in order to explain the present invention in detail, examples are given, but the present invention is not limited to these examples.
実施例 ヒトの皮膚表面に常在するアクネ菌の１６ｓ ｒＲＮＡ量と赤ニキビの関係
ニキビができやすい５名（被験者Ａ：３０歳男性、被験者Ｂ：２９歳男性、被験者Ｃ：３１歳男性、被験者Ｄ：２８歳男性、被験者Ｅ：４５歳女性）を被験者とし、額を被験部位とした。赤ニキビの発生は、２４時間おきに目視にて観察した。また、同時に２％ポリソルベート８０水溶液を含ませた綿棒を用いて、額の５ｃｍ２の範囲を拭き取り、試料とした。
ＲＮＡ量は文献（Ａｐｐｌ Ｅｎｖｉｒｏｎ Ｍｉｃｒｏｂｉｏｌ ７５，１９６１−１９６９，２００９）を参考にして測定した。すなわち、試料（綿棒の拭き取り部）をエッペンドルフチューブに入れ、ＲＮＡ ｐｒｏｔｅｃｔ Ｂａｃｔｅｒｉａ Ｒｅａｇｅｎｔ（Ｑｉａｇｅｎ）を添加、撹拌し、２２．５℃で５分間処理した。液体部分を採取し、メンブランフィルター（０．４５μｍ）を用いてろ過した後、メンブランフィルターを凍結保存した。自然解凍後、溶菌バッファー（Ｂｕｆｆｅｒ ＲＬＴ（Ｑｉａｇｅｎ）３４６．５μＬ、メルカプトエタノール３．５μＬ、ＴＥ ｂｕｆｆｅｒ（１０ｍＭ Ｔｒｉｓ−ＨＣｌ、１ｍＭ ＥＤＴＡ［ｐＨ８．０］）１００μＬ）とガラスビーズ（０．１ｍｍ）３００ｍｇを添加、撹拌した後、フィルターを取り除いた。水飽和フェノール５００μＬを添加し、６０℃１０分間反応させた。クロロホルム／イソアミルアルコール（２４：１）抽出後、イソプロピルアルコール処理を行い、沈渣をＮｕｃｌｅａｓｅ ｆｒｅｅ水で溶解した。試料中に混在するＤＮＡはＤＮａｓｅ処理にて除去した。すなわち、２０ＵのＤＮａｓｅ（タカラ）を添加し、３７℃にて２０分間反応させた。水飽和フェノール及びクロロホルム／イソアミルアルコール（２４：１）による抽出を行った後、イソプロピルアルコール処理を行い、沈渣をＮｕｃｌｅａｓｅ ｆｒｅｅ 水で溶解した。その後、採取したＲＮＡをｃＤＮＡに転写し、リアルタイムＰＣＲにて１６ｓ ｒＲＮＡ相対量（Ｃｔ値）を測定した。なお、ＲＮＡ量の測定に使用したプライマーは、次の通りである。
Example Relationship between the amount of 16s rRNA of acne bacteria resident on the human skin surface and red acne 5 subjects (subject A: 30-year-old male, subject B: 29-year-old male, subject C: 31-year-old male, subject) D: 28-year-old male, subject E: 45-year-old female) was the subject, and the forehead was the test site. The occurrence of red acne was visually observed every 24 hours. At the same time, a 5 cm 2 range of the forehead was wiped off using a cotton swab containing a 2% polysorbate 80 aqueous solution as a sample.
The amount of RNA was measured with reference to the literature (Appl Environ Microbiol 75, 1961-1969, 2009). Specifically, a sample (a swab of a cotton swab) was placed in an Eppendorf tube, RNA protect Bacteria Reagent (Qiagen) was added, stirred, and treated at 22.5 ° C. for 5 minutes. The liquid part was collected and filtered using a membrane filter (0.45 μm), and the membrane filter was stored frozen. After natural thawing, lysis buffer (Buffer RLT (Qiagen) 346.5 μL, mercaptoethanol 3.5 μL, TE buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]) 100 μL) and glass beads (0.1 mm) 300 mg were added. After addition and stirring, the filter was removed. 500 μL of water-saturated phenol was added and reacted at 60 ° C. for 10 minutes. After extraction with chloroform / isoamyl alcohol (24: 1), isopropyl alcohol treatment was performed, and the precipitate was dissolved with Nuclease free water. DNA mixed in the sample was removed by DNase treatment. That is, 20 U DNase (Takara) was added and reacted at 37 ° C. for 20 minutes. After extraction with water-saturated phenol and chloroform / isoamyl alcohol (24: 1), the mixture was treated with isopropyl alcohol, and the precipitate was dissolved with Nuclease free water. Thereafter, the collected RNA was transferred to cDNA, and the 16s rRNA relative amount (Ct value) was measured by real-time PCR. In addition, the primer used for the measurement of RNA amount is as follows.
アクネ菌の１６ｓ ｒＲＮＡ用のプライマーセット
ＧＣＧＴＧＡＧＴＧＡＣＧＧＴＡＡＴＧＧＧＴＡ（配列番号１）
ＴＴＣＣＧＡＣＧＣＧＡＴＣＡＡＣＣＡ（配列番号２）
Primer set GCGTGGATGGACGTAATGGGGTA for 16s rRNA of Acne (SEQ ID NO: 1)
TTCCGACGCGATCAACCA (SEQ ID NO: 2)
ＤＮＡ量は文献（Ｊ Ｄｅｒｍａｔｏｌ ４３，９０６−９１１，２０１６）を参考にして測定した。すなわち、試料をチューブに入れ、１．５倍量のＬｙｓｉｎｇ ｓｏｌｕｔｉｏｎ（１００ｍＭ Ｔｒｉｓ−ＨＣｌ、３０ｍＭ ＥＤＴＡ、０．５％ ｓｏｄｉｕｍ ｄｏｄｅｃｙｌ ｓｕｌｆａｔｅ）を２００μＬ添加、撹拌した。１００℃１５分間の反応後、液体部分を採取し、フェノール／クロロホルム／イソアミルアルコール（２５：２４：１）抽出、イソプロピルアルコール処理後、沈渣をＴＥ ｂｕｆｆｅｒに溶解した。その後、ＲＮＡ測定と同様の方法で、１６ｓ ｒＲＮＡ相対量（Ｃｔ値）を測定した。
生菌数は、培養法によって測定した。試料をリン酸緩衝液（ｐＨ７．０）に分散し、段階希釈後、変法ＧＡＭ寒天培地（日水製薬）に塗抹した。３５℃で７日間嫌気培養し、発現したコロニーのうち、グラム陽性桿菌をアクネ菌と判断し、コロニー数を計測した。
The amount of DNA was measured with reference to literature (J Dermatol 43,906-911, 2016). That is, a sample was placed in a tube, and 200 μL of 1.5 times amount of Lysing solution (100 mM Tris-HCl, 30 mM EDTA, 0.5% sodium dodecyl sulfate) was added and stirred. After the reaction at 100 ° C. for 15 minutes, the liquid portion was collected, extracted with phenol / chloroform / isoamyl alcohol (25: 24: 1), treated with isopropyl alcohol, and the precipitate was dissolved in TE buffer. Thereafter, the relative amount of 16s rRNA (Ct value) was measured by the same method as RNA measurement.
The number of viable bacteria was measured by a culture method. The sample was dispersed in a phosphate buffer (pH 7.0), and after serial dilution, it was smeared on a modified GAM agar medium (Nissui Pharmaceutical). Anaerobic culture was carried out at 35 ° C. for 7 days, and among the expressed colonies, Gram-positive bacilli were determined as acne bacteria, and the number of colonies was counted.
被験者Ａにおける赤ニキビの発生、アクネ菌のＲＮＡ、ＤＮＡ及び生菌数の解析結果を図１に示す。 FIG. 1 shows the results of red acne generation, RNA and DNA of acne bacteria, and the number of viable bacteria in subject A.
赤ニキビが発生する２４時間前に、アクネ菌のＲＮＡ量が２倍以上に増加した。アクネ菌のＤＮＡ及び生菌数は、２倍以上の増加を示さなかった。 24 hours before the occurrence of red acne, the RNA amount of acne bacteria increased more than twice. Acne bacteria DNA and viable cell counts did not increase more than 2-fold.
被験者Ｂにおける赤ニキビの発生、アクネ菌のＲＮＡ、ＤＮＡ及び生菌数の解析結果を図２に示す。 FIG. 2 shows the results of red acne generation, RNA and DNA of acne bacteria, and the number of viable bacteria in subject B.
赤ニキビが発生する２４時間前に、アクネ菌のＲＮＡ量が２倍以上に増加した。アクネ菌のＤＮＡ及び生菌数は、２倍以上の増加を示さなかった。 24 hours before the occurrence of red acne, the RNA amount of acne bacteria increased more than twice. Acne bacteria DNA and viable cell counts did not increase more than 2-fold.
被験者Ｃにおける赤ニキビの発生、アクネ菌のＲＮＡ、ＤＮＡ及び生菌数の解析結果を図３に示す。 FIG. 3 shows the results of red acne occurrence, RNA and DNA of acne bacteria, and the number of viable bacteria in subject C.
赤ニキビが発生する２４時間前に、アクネ菌のＲＮＡ量が２倍以上に増加した。アクネ菌のＤＮＡ及び生菌数は、２倍以上の増加を示さなかった。 24 hours before the occurrence of red acne, the RNA amount of acne bacteria increased more than twice. Acne bacteria DNA and viable cell counts did not increase more than 2-fold.
被験者Ｄにおける赤ニキビの発生、アクネ菌のＲＮＡ、ＤＮＡ及び生菌数の解析結果を図４に示す。 FIG. 4 shows the results of red acne generation, RNA and DNA of acne bacteria, and the number of viable bacteria in subject D.
赤ニキビが発生する２４時間前に、アクネ菌のＲＮＡ量が２倍以上に増加した。アクネ菌のＤＮＡ及び生菌数は、２倍以上の増加を示さなかった。 24 hours before the occurrence of red acne, the RNA amount of acne bacteria increased more than twice. Acne bacteria DNA and viable cell counts did not increase more than 2-fold.
被験者Ｅにおける赤ニキビの発生、アクネ菌のＲＮＡ、ＤＮＡ及び生菌数の解析結果を図５に示す。 FIG. 5 shows the results of red acne generation, RNA and DNA of acne bacteria, and the number of viable bacteria in subject E.
赤ニキビが発生する２４時間前に、アクネ菌のＲＮＡ量が２倍以上に増加した。アクネ菌のＤＮＡ及び生菌数は、２倍以上の増加を示さなかった。 24 hours before the occurrence of red acne, the RNA amount of acne bacteria increased more than twice. Acne bacteria DNA and viable cell counts did not increase more than 2-fold.
以上の結果から、アクネ菌のＲＮＡ量を測定することで、赤ニキビの発生を予測できることが判明した。また、本発明の方法は、赤ニキビの発生を予防する物質のスクリーニングに利用可能である。 From the above results, it was found that the occurrence of red acne can be predicted by measuring the RNA amount of acne bacteria. In addition, the method of the present invention can be used for screening for substances that prevent the occurrence of red acne.
本発明の皮膚上に常在するアクネ菌のＲＮＡ量を指標とした方法によって、赤ニキビの発生を予測することが可能である。さらにまた、検査対象の試料採取が非侵襲的、且つ容易であり、対象者の負担が少なく簡便に測定することができる。以上に加えて、赤ニキビの発生を予防する物質のスクリーニングを行うことができる。 The occurrence of red acne can be predicted by the method using the RNA amount of acne bacteria resident on the skin of the present invention as an index. Furthermore, it is non-invasive and easy to collect a sample to be examined, and the measurement can be easily performed with less burden on the subject. In addition to the above, screening for substances that prevent the occurrence of red acne can be performed.
Claims (4)
The step of collecting acne bacteria resident on the skin over time, the step of measuring the RNA amount of collected acne bacteria, and the amount of RNA of interest is 2 (n / 24) A method for predicting the occurrence of red acne, comprising the step of confirming that it has increased by a factor of two or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018106604A JP7081802B2 (en) | 2018-06-04 | 2018-06-04 | How to Predict Red Acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018106604A JP7081802B2 (en) | 2018-06-04 | 2018-06-04 | How to Predict Red Acne |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019208419A true JP2019208419A (en) | 2019-12-12 |
| JP7081802B2 JP7081802B2 (en) | 2022-06-07 |
Family
ID=68843886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018106604A Active JP7081802B2 (en) | 2018-06-04 | 2018-06-04 | How to Predict Red Acne |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7081802B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185685A1 (en) * | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| WO2024070185A1 (en) * | 2022-09-30 | 2024-04-04 | 株式会社Kins | Biomarker and determination assistance method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500010A (en) * | 2002-07-18 | 2006-01-05 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | Microorganism detection oligonucleotide |
| JP2011514159A (en) * | 2008-02-19 | 2011-05-06 | ジェン−プロウブ インコーポレイテッド | Compositions and methods for detecting nucleic acids of Propionibacterium acnes |
| JP2014095608A (en) * | 2012-11-09 | 2014-05-22 | Nippon Menaade Keshohin Kk | Method of estimating number of propionibacterium acnes always extending in skin |
| JP2016095185A (en) * | 2014-11-13 | 2016-05-26 | 株式会社ファンケル | Acne skin evaluation method |
| JP2017029174A (en) * | 2015-07-21 | 2017-02-09 | ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 | Method for evaluating physical conditions, method for presenting information, and method of screening for substance for improving or preventing physical conditions |
-
2018
- 2018-06-04 JP JP2018106604A patent/JP7081802B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500010A (en) * | 2002-07-18 | 2006-01-05 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | Microorganism detection oligonucleotide |
| JP2011514159A (en) * | 2008-02-19 | 2011-05-06 | ジェン−プロウブ インコーポレイテッド | Compositions and methods for detecting nucleic acids of Propionibacterium acnes |
| JP2014095608A (en) * | 2012-11-09 | 2014-05-22 | Nippon Menaade Keshohin Kk | Method of estimating number of propionibacterium acnes always extending in skin |
| JP2016095185A (en) * | 2014-11-13 | 2016-05-26 | 株式会社ファンケル | Acne skin evaluation method |
| JP2017029174A (en) * | 2015-07-21 | 2017-02-09 | ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 | Method for evaluating physical conditions, method for presenting information, and method of screening for substance for improving or preventing physical conditions |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185685A1 (en) * | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| WO2024070185A1 (en) * | 2022-09-30 | 2024-04-04 | 株式会社Kins | Biomarker and determination assistance method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7081802B2 (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110033842A1 (en) | Skin Sampling Kit Which Stores Nucleic Acids In Stable Status, Genetic Test Methods By Using The Kit And Their Practical Application | |
| JP2020508689A (en) | Non-invasive method for skin sample collection and analysis | |
| JP2020074769A (en) | Method for preparing nucleic acid derived from skin cells of subject | |
| JP6033435B2 (en) | Antibacterial composition containing a phyllobasidium inhibitor derived from a natural product | |
| CN107922979A (en) | The screening technique of the material of the evaluation method of physical condition, the reminding method of information and improvement or prevention physical condition | |
| Wang et al. | Why minimally invasive skin sampling techniques? A bright scientific future | |
| JP7081802B2 (en) | How to Predict Red Acne | |
| Baptista et al. | DNA methylation levels of SOCS1 and LINE-1 in oral epithelial cells from aggressive periodontitis patients | |
| TW202237080A (en) | Hair restorer | |
| EP3673270A1 (en) | Diagnostic method of a skin showing signs of aging | |
| KR101267430B1 (en) | New Skin Sampling Kit Which Stores Nucleic Acids in Stable Status, Genetic Test Methods by using the kit and Their Practical Application | |
| Barber et al. | Tape stripping: investigational, diagnostic, and therapeutic uses in dermatology | |
| DE102017119427A1 (en) | Determining the age of a human individual | |
| Omodo-Eluk et al. | Comparison of two sampling techniques for the detection of Malassezia pachydermatis on the skin of dogs with chronic dermatitis | |
| Balayan et al. | Chimeric status of biological samples after HSCT for personal identification: Y-STR based DNA analysis in sex mismatch cases | |
| Wadhwani et al. | Effect of scaling and root planing on detection of Tannerella forsythia in chronic periodontitis | |
| JP6397733B2 (en) | Acne Skin Evaluation Method | |
| JP2010115178A (en) | Method of forecasting skin inflammation and application of the same | |
| JP2011083207A (en) | Method for evaluating epidermal turnover and application thereof | |
| CN110904193B (en) | Method for selecting systemic lupus erythematosus skin microbial diagnosis marker | |
| Kubba et al. | Pathogenesis of acne | |
| Tahir et al. | Role of direct immunofluorescence on Tzanck smear and plucked hair in the diagnosis of pemphigus vulgaris | |
| JP2019144045A (en) | Determination method for treatment effect prediction in atopic dermatitis treatment using mesenchymal stem cells | |
| JP2016216436A (en) | Skin viscoelasticity improver | |
| O'Shaughnessy-Hunter | The cutaneous microbiota of healthy horses in one barn in Ontario and evaluation of the effect of individual, skin site & season on bacterial composition and diversity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210423 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220318 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220510 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220519 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7081802 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |